Current HIV guidelines limit their recommendations for dual ART, but I expect positive data will soon change this.
The question of which patients are candidates for long-acting ART might be a question of which patients want it.
Less frequent dosing may be a welcome theme among HIV drugs under investigation.
Why I believe as many as 70% of my patients will be interested in long-acting injectable ART.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.